• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

    10/9/24 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTGN alert in real time by email

    Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024

    Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health

    Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join together in New York City on October 10, 2024 to ring the Nasdaq Closing Bell in honor of World Mental Health Day and The Goldie Hawn Foundation's 20th Anniversary.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009774485/en/

    Vistagen CEO Shawn Singh and Goldie Hawn, along with MindUP students will ring the Nasdaq Closing Bell together in a joint ceremony to highlight the power of partnership and shared commitment to advance neuroscience-based innovation.

    "Mental well-being is foundational for a healthy life, and it starts with understanding how our brains work," said Goldie Hawn, Founder of The Goldie Hawn Foundation and innovator of its MindUP program. "Our mission has always been to equip children with the tools to understand their brain and build mental fitness and resilience. We are ringing the bell with Vistagen today in an effort to invite leaders from across the country to join our work to advance investment in our most important resource, our children."

    "At Vistagen, we believe in the importance of a multifaceted approach to improving mental health through heightened awareness, innovative education, and improved patient care," said Shawn Singh, CEO of Vistagen. "Driven by pioneering neuroscience-based research, Vistagen and MindUp can make a positive difference in the mental health and well-being of millions of children and adults around the world."

    About World Mental Health Day

    World Mental Health Day aims to raise awareness of mental health issues around the world and to mobilize efforts in support of mental health. According to the World Health Organization, in 2019, 970 million people globally were living with a mental health disorder, with anxiety and depression the most common. Mental health conditions can cause difficulties in all aspects of life, including emotional well-being, relationships, physical health, and ability to function at work or school. Left untreated, these issues can lead to chronic stress, social isolation, and an increased risk of other health complications. Creating a range of solutions such as therapy, medication, education, community support, and lifestyle changes, can help individuals find care that suits their unique needs, ultimately leading to better mental health outcomes and a healthier society.

    About Vistagen

    Headquartered in South San Francisco, CA, Vistagen (NASDAQ:VTGN) is a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders. Based on its pioneering approach and deep understanding of nose-to-brain neurocircuitry, Vistagen's diversified neuroscience pipeline includes non-systemic pherine nasal spray product candidates designed to rapidly activate chemosensory neurons in the nasal cavity to impact olfactory system and brain neurocircuitry. Vistagen's most advanced pherine candidate, fasedienol, is in a U.S. registration-directed Phase 3 development program for the acute treatment of social anxiety disorder, which affects over 30 million adults in the U.S. Vistagen is passionate about its mission to deliver novel and differentiated treatments that set new standards of care for millions of people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.

    About The Goldie Hawn Foundation's MindUP program

    The Goldie Hawn Foundation's MindUP program provides evidence-based training to help youth, educators, and families develop the mental fitness needed to thrive in school, work, and life. Founded in 2003, it is the signature program of The Goldie Hawn Foundation, a not-for-profit organization created in response to the global epidemic of childhood aggression, anxiety, depression, and suicide. Based firmly on neuroscience, MindUP provides children with the skills and knowledge to successfully manage stress, regulate emotions, and face the challenges of today. Learn more at MindUP.org.

    Forward-looking Statements

    This press release contains certain forward-looking statements made by Vistagen within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "project," "outlook," "strategy," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "strive," "goal," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. These uncertainties, risks, and other matters are more fully discussed in the section entitled "Risk Factors" in filings Vistagen makes with the U.S. Securities and Exchange Commission (SEC) from time to time. Vistagen's SEC filings are available on the SEC's website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen's views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241009774485/en/

    Get the next $VTGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTGN

    DatePrice TargetRatingAnalyst
    12/7/2023$15.00Hold → Buy
    Jefferies
    8/7/2023$30.00Hold → Buy
    Maxim Group
    7/22/2022Outperform → Neutral
    Robert W. Baird
    7/22/2022Buy → Hold
    Jefferies
    7/22/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $VTGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

    Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women's health, and cancer supportive care Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a

    8/7/25 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 1

    7/31/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Present at the BTIG Virtual Biotechnology Conference

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact yo

    7/24/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.

    SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    8/14/25 5:13:28 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Vistagen Therapeutics Inc.

    10-Q - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    8/7/25 4:57:51 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    8/7/25 4:56:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Prince Joshua S. was granted 4,882 shares, increasing direct ownership by 82% to 10,863 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/1/25 5:51:38 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Adler Reid G. was granted 7,541 shares, increasing direct ownership by 46% to 24,050 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/1/25 5:50:42 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 6,617 shares, increasing direct ownership by 107% to 12,801 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/1/25 5:49:44 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VistaGen upgraded by Jefferies with a new price target

    Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00

    12/7/23 6:31:15 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen upgraded by Maxim Group with a new price target

    Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00

    8/7/23 2:16:37 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Robert W. Baird

    Robert W. Baird downgraded VistaGen from Outperform to Neutral

    7/22/22 12:22:03 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

    Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead t

    6/25/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

    Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget

    10/9/24 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Appoints Cindy Anderson as Chief Financial Officer

    Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V

    8/22/23 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 4:19:46 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    2/14/24 6:18:34 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Financials

    Live finance-specific insights

    View All

    Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

    Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women's health, and cancer supportive care Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a

    8/7/25 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 1

    7/31/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

    Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corp

    6/17/25 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care